Tilray Stock Rises As Study Links Medical Cannabis To Lower Opioid Use
1. TLRY shares rose 5% following cannabis reduction in opioid prescriptions. 2. Cannabis legalization correlated with 16% decline in opioid prescriptions per study. 3. Greater reductions noted for specific groups, enhancing TLRY's growth potential. 4. The stock shows strong momentum, ranking 93.42 according to Benzinga Edge. 5. Trading significantly above moving averages indicates positive technical momentum.